CV Lattes
ResearcherID
ORCID
Google Scholar Citations
Universidade de São Paulo (USP). Instituto de Ciências Biomédicas (ICB) (Institutional affiliation from the last research proposal) Birthplace: Brazil
He holds a degree in Biological Sciences from the Federal University of Rio de Janeiro (1978), a Master's degree in Biological Sciences (Biophysics) from the Federal University of Rio de Janeiro (1982) and a PhD in Biological Sciences (Biophysics) from the Federal University of Rio de Janeiro (1985). ). He carried out postdoctoral internships at the Max-Planck Institute in Tuebingen, Germany (1986/7), Center for Vaccine Development at the University of Maryland, USA (1991), Department of Microbiology and Molecular Biology at Tufts University, USA (1992 ) and Department of Medical Microbiology at the University of Gothenburg, Sweden (1996). Visiting Researcher at the Institute of Genetics at the University of Bayreuth, Germany (2000-2005). Adjunct Professor at the Department of Biophysics and Radiobiology at the Federal University of Pernambuco (1983-1989) and at the Carlos Chagas Filho Institute of Biophysics at the Federal University of Rio de Janeiro (1989-2000). He is currently a professor (1999) and full professor (2000) at the University of São Paulo and responsible for the Vaccine Development Laboratory at the Department of Microbiology at the Institute of Biomedical Sciences. Researcher 1A of the National Council for Scientific and Technological Development. Director of the Institute of Biomedical Sciences at USP (2017-2021). Coordinator of the Pasteur-USP Scientific Platform (2018-2023). President of the Deliberative Council of the USP/IPEN business incubator (CIETEC), member of the Health and Biotechnology Productive Chain Committee (Comsaude) of FIESP. He received several awards related to scientific work and technological innovation. He encouraged and participated in the creation of two USP spinoff companies. He has experience in the areas of Microbiology, Molecular and Microorganism Genetics, immunology, serological diagnostic methods and vaccine development. He develops different vaccine technologies, such as mucosal vaccines, subunit vaccines, vaccines with attenuated and vectorized microorganisms, genetic vaccines (DNA and mRNA), polyepitope vaccines and protein vaccine adjuvants. Developed vaccine formulations aimed at controlling diarrhea caused by enteric bacteria (diarrheogenic Escherichia coli and Salmonella), dengue virus, Zika, chikungunya, coronavirus, Streptococcus mutans and S. agalactiae, paracoccidioid mycosis, malaria and tumors induced by papilloma virus. He has published around 220 scientific articles in specialized journals. He has patents granted in Brazil and the USA. (Source: Lattes Curriculum)
| Articles published in Pesquisa FAPESP Magazine about the researcher: |
| Articles published in Pesquisa para Inovação FAPESP about the researcher: |
| FAPESP-funded startups are developing COVID-19 vaccines |
| More itemsLess items |
| News published in Agência FAPESP Newsletter about the researcher |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
More than three years after COVID-19 (Coronavirus disease 2019) was triggered, with more than 770 million human cases and almost 7 million deaths, in May this year, the World Health Organization declared the end of this disease as a public health emergency. However, the end of the state of emergency does not imply the end of the pandemic: SARS-CoV-2 (Severe acute respiratory syndrome coro…
Bacteriophages are viruses that infect bacteria and represent a natural source for the identification of antimicrobial molecules. Among these molecules are endolysins, enzymes that degrade the cell wall at the end of the bacteriophage lytic cycle and are specific at the level of bacterial species. Numerous studies have tested the activity of these enzymes against Gram-positive bacteria, s…
Vaccines, as public health strategies, are the best method for the long-term prevention (and/or treatment) of infectious diseases, since they play a key role in strengthening the immune response of each individual, reducing the spread of the pathogen. and limiting the possible outbreak (endemic, epidemic or pandemic) that it may cause. The use of adjuvants in the manufacture of vaccines b…
(Only some records are available in English at this moment)
Vaccines, as public health strategies, are the best method for the long-term prevention (and/or treatment) of infectious diseases, since they play a key role in strengthening the immune response of each individual, reducing the spread of the pathogen. and limiting the possible outbreak (endemic, epidemic or pandemic) that it may cause. The use of adjuvants in the manufacture of vaccines b…
SARS-CoV-2 has become a threat to global public health, by breaking a barrier between the species of acute human syndromes and causing a type of acute infection that is highly transmissible between humans, called COVID-19, and is distributed around the world, with serious intent in a pandemic. The offer of high genetic studies for vaccines vaccines for use in the main glycoprotein at the …
(Only some records are available in English at this moment)
COVID-19 is a viral infection with high transmission potential and broad clinical spectrum, caused by the SARS-CoV-2 virus. The first case of the disease was identified in Wuhan, China, in 2019 and it only took a few months for it to cross continental borders and then be recognized by the World Health Organization (WHO) as a pandemic. Over the more than three years that followed this adve…
The outbreak of COVID-19, severe acute respiratory syndrome caused by coronavirus type 2 (SARS-CoV-2), began in China and spread around the world as a pandemic with more than 5 million deaths worldwide and more of 617 thousand deaths in Brazil. Even with the rapid development and distribution of vaccines to the population, the virus continues to spread around the world, thus maintaining t…
Cervical cancer stands out due to the high mortality rate worldwide. Despite the available treatments, cervical cancer is still considered a public health problem and new therapeutic approaches are needed. The objective of this project is to evaluate a treatment composed of immunotherapy based on bone marrow differentiated dendritic cells (BMDCs) activated in vitro by the recombinant prot…
In view of the current COVID-19 pandemic, the development of vaccination strategies against SARS-CoV-2 is a priority. Considering that risk groups are a priority, it is essential to develop vaccination strategies that have an adequate safety profile. In this context, subunits vaccines have been shown to be a promising alternative because they are safer, although they are often less immuno…
(Only some records are available in English at this moment)
The COVID-19 pandemic has been an unprecedented situation regarding its fast spread and the associated economical losses. Since late 2019 when it first emerged, SARS-CoV-2 has already caused millions of deaths worldwide and despite vaccination efforts continues to escalate. Even though several vaccines are already commercially available, they still face several limitations that open space…
Synthetic peptides have been described as potent and specific antiviral agents. Inhibitory peptides with effect on flaviviruses, including the arbovirus DENV and ZIKV, have also been investigated but so far no one is available for clinical use. On this line, our research group identified a peptide (Pep. 47), derived from DENV E protein domain III (EDIII) that have in vitro inhibitory effe…
Cervical cancer is the third leading cause of cancer death in women and is associated with persistent infection with Human Papilloma Virus (HPV) in more than 99% of the cases. Given the epidemiological relevance of tumors induced by HPV, development of effective therapeutic vaccines is a high priority. Therefore, we have developed a DNA-based therapeutic vaccine encoding the HPV-16 E7 pro…
(Only some records are available in English at this moment)
| 4 / 4 | Ongoing grants |
| 33 / 23 | Completed research grants |
| 1 / 1 | Ongoing scholarships in Brazil |
| 73 / 33 | Completed scholarships in Brazil |
| 9 / 7 | Completed scholarships abroad |
| 120 / 68 | All research grants and scholarships |
| Associated processes | |